Important Details on ADMA Biologics, Inc. Class Action Lawsuit and Your Options as Investor

ADMA Biologics, Inc. Class Action Lawsuit: Key Information for Investors

In recent developments, ADMA Biologics, Inc., a biopharmaceutical company listed on NASDAQ under the symbol ADMA, is facing significant legal challenges due to a class action lawsuit pertaining to securities fraud. This lawsuit has implications for those who purchased ADMA securities between August 9, 2024, and March 25, 2026. The following article outlines the critical details surrounding the lawsuit and the necessary actions affected investors can take.

Overview of the Lawsuit

The class action lawsuit was initiated in the United States District Court for the District of New Jersey. It centers around allegations that ADMA Biologics made materially false and misleading statements regarding its revenue and internal control systems. Plaintiffs claim that throughout the defined class period, the company's executives engaged in practices that misrepresented the actual financial conditions, potentially leading to significant investor losses.

The allegations suggest that ADMA Biologics was involved in deceptive practices, including undisclosed related party transactions and channel stuffing to artificially inflate revenue figures. These actions are said to have tainted investors' perspectives on the company's operations and future growth.

The Consequences of False Information

The repercussions of these allegations were starkly illustrated on March 24, 2026, when Culper Research published a report accusing ADMA Biologics of employing dubious tactics like “channel stuffing.” Following this report, the share price of ADMA Biologics plummeted by approximately 29.1% over two trading days, dropping to $9.63 per share—a clear sign that the market reacted adversely to the revelations.

Important Deadlines and Actions for Investors

Affected investors have until August 10, 2026, to file for lead plaintiff status in this lawsuit. The lead plaintiff will act on behalf of all class members and play a vital role in directing litigation. As a potential lead plaintiff, you should consider engaging with a qualified attorney who specializes in securities litigation to discuss your case's merits and strategic options.

Steps to Take:

1. Contact Legal Counsel: Kessler Topaz Meltzer Check, LLP is representing plaintiffs in this case. Investors can reach out to them for a free case evaluation. Contact information is available through their website.
2. Gather Evidence: If you invested in ADMA between the specified dates, collect all relevant documents, including purchase confirmations and account statements.
3. Evaluate Your Position: Decide if you want to seek lead plaintiff status or remain an absent class member. Choosing to serve as the lead can offer you a voice in the proceedings, although your potential recovery would not be contingent upon this decision.

Conclusion

The ongoing class action against ADMA Biologics represents a significant moment for investors affected by the company's alleged misconduct. With the August deadline approaching, it is imperative for affected parties to assess their situation and act promptly to protect their rights. Engaging with legal professionals and being proactive in understanding your options can have a lasting impact on the outcome of this litigation.

Investors are encouraged to stay informed and act within the stipulated deadlines as the situation unfolds. For more information, please consult the aforementioned law firm or trusted financial advisors.